Phase I modular study of AZD6738, a novel oral, potent and selective ataxia telangiectasia Rad3-related (ATR) inhibitor in combination (combo) with carboplatin, olaparib or durvalumab in patients (pts) with advanced cancers

Louise Carter

Phase I modular study of AZD6738, a novel oral, potent and selective ataxia telangiectasia Rad3-related (ATR) inhibitor in combination (combo) with carboplatin, olaparib or durvalumab in patients (pts) with advanced cancers

FBMH Faculty Office Administration (L5)

Research output: Contribution to journal › Article

Original language	Undefined
Journal	European Journal of Cancer
Publication status	Published - 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{6bb7b778511e43e4917e0e01a95fd751,

title = "Phase I modular study of AZD6738, a novel oral, potent and selective ataxia telangiectasia Rad3-related (ATR) inhibitor in combination (combo) with carboplatin, olaparib or durvalumab in patients (pts) with advanced cancers",

author = "Louise Carter",

year = "2016",

language = "Undefined",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier BV",

}

TY - JOUR

T1 - Phase I modular study of AZD6738, a novel oral, potent and selective ataxia telangiectasia Rad3-related (ATR) inhibitor in combination (combo) with carboplatin, olaparib or durvalumab in patients (pts) with advanced cancers

AU - Carter, Louise

PY - 2016

Y1 - 2016

M3 - Article

SN - 0959-8049

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -